Real-world effectiveness and persistence of methotrexate versus adalimumab: A comparative study from the British association of dermatologists biologics and immunomodulators register (BADBIR)

O Alabas; K Mason; Z Yiu; R Warren; M Lunt; C Smith; C Griffiths

Real-world effectiveness and persistence of methotrexate versus adalimumab: A comparative study from the British association of dermatologists biologics and immunomodulators register (BADBIR)

O Alabas, K Mason, Z Yiu, R Warren, M Lunt, C Smith, C Griffiths

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	490-490
Number of pages	1
Journal	Pharmacoepidemiology and Drug Safety
Volume	31
Publication status	Published - Sep 2022

Cite this

@article{63f6ec3b689846858a5e4b9817f2f296,

title = "Real-world effectiveness and persistence of methotrexate versus adalimumab: A comparative study from the British association of dermatologists biologics and immunomodulators register (BADBIR)",

author = "O Alabas and K Mason and Z Yiu and R Warren and M Lunt and C Smith and C Griffiths",

year = "2022",

month = sep,

language = "English",

volume = "31",

pages = "490--490",

journal = "Pharmacoepidemiology and Drug Safety",

issn = "1053-8569",

publisher = "John Wiley & Sons Ltd",

}

Real-world effectiveness and persistence of methotrexate versus adalimumab : A comparative study from the British association of dermatologists biologics and immunomodulators register (BADBIR). / Alabas, O; Mason, K; Yiu, Z et al.

In: Pharmacoepidemiology and Drug Safety , Vol. 31, 09.2022, p. 490-490.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Real-world effectiveness and persistence of methotrexate versus adalimumab

T2 - A comparative study from the British association of dermatologists biologics and immunomodulators register (BADBIR)

AU - Alabas, O

AU - Mason, K

AU - Yiu, Z

AU - Warren, R

AU - Lunt, M

AU - Smith, C

AU - Griffiths, C

PY - 2022/9

Y1 - 2022/9

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000859084402173&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

VL - 31

SP - 490

EP - 490

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

ER -

Real-world effectiveness and persistence of methotrexate versus adalimumab: A comparative study from the British association of dermatologists biologics and immunomodulators register (BADBIR)

Other files and links

Cite this